Numerous studies have reported a higher expression of IL-17A in tumor cells, including breast cancer, colorectal carcinoma, gastric carcinoma, hepatocellular carcinoma, ovarian cancer, medulloblastoma, pancreatic cancer, non-small-cell lung cancer, and thyroid cancer [18, 19]. This evidence concerns the gene IL17A and hepatocellular carcinoma.